Literature DB >> 20924400

Hereditary disorders of renal phosphate wasting.

Amir S Alizadeh Naderi1, Robert F Reilly.   

Abstract

Inherited diseases of renal phosphate handling lead to urinary phosphate wasting and depletion of total body phosphorus stores. Clinical sequelae of inherited disorders that are associated with increased urinary phosphate excretion are deleterious and can lead to abnormal skeletal growth and deformities. This Review describes hereditary disorders of renal phosphate wasting taking into account developments in our understanding of renal phosphate handling from the last decade. The cloning of genes involved in these disorders and further studies on their pathophysiological mechanisms have given important insights in to how phosphatonins, such as FGF-23, regulate renal phosphate reabsorption in health and disease. X-linked dominant hypophosphatemic rickets results from mutation of a metalloprotease (PHEX) that has an unidentified role in FGF-23 degradation. Mutation of an RXXR proteolytic cleavage site in FGF-23 prevents degradation and increases circulating levels of FGF-23 in autosomal dominant hypophosphatemic rickets. FGF-23 acts to remove sodium phosphate co-transporters from the luminal membrane of proximal tubular cells with resultant renal phosphate wasting. Loss of function mutations in genes encoding the transporters NaPi-IIc and NaPi-IIa also result in renal phosphate wasting and rickets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924400     DOI: 10.1038/nrneph.2010.121

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  96 in total

1.  Bone as a source of FGF23: regulation by phosphate?

Authors:  Michiko Mirams; Bruce G Robinson; Rebecca S Mason; Anne E Nelson
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

2.  Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets.

Authors:  I A Holm; X Huang; L M Kunkel
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

3.  Renal transplantation in hypophosphatemia with vitamin D-resistant rickets.

Authors:  J M Morgan; W L Hawley; A I Chenoweth; W J Retan; A G Diethelm
Journal:  Arch Intern Med       Date:  1974-09

4.  Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder.

Authors:  M J Econs; P T McEnery
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

5.  The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi.

Authors:  Ricardo Villa-Bellosta; Silvia Ravera; Victor Sorribas; Gerti Stange; Moshe Levi; Heini Murer; Jürg Biber; Ian C Forster
Journal:  Am J Physiol Renal Physiol       Date:  2008-12-10

6.  A patient with hypophosphatemia, a femoral fracture, and recurrent kidney stones: report of a novel mutation in SLC34A3.

Authors:  Kathleen Page; Clemens Bergwitz; Graciana Jaureguiberry; Chittari V Harinarayan; Karl Insogna
Journal:  Endocr Pract       Date:  2008-10       Impact factor: 3.443

7.  Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification.

Authors:  Frank Rutsch; Nico Ruf; Sucheta Vaingankar; Mohammad R Toliat; Anita Suk; Wolfgang Höhne; Galen Schauer; Mandy Lehmann; Tony Roscioli; Dirk Schnabel; Jörg T Epplen; Alex Knisely; Andrea Superti-Furga; James McGill; Marco Filippone; Alan R Sinaiko; Hillary Vallance; Bernd Hinrichs; Wendy Smith; Merry Ferre; Robert Terkeltaub; Peter Nürnberg
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

8.  Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development.

Authors:  Hiroko Segawa; Akemi Onitsuka; Junya Furutani; Ichiro Kaneko; Fumito Aranami; Natsuki Matsumoto; Yuka Tomoe; Masashi Kuwahata; Mikiko Ito; Mitsuru Matsumoto; Minqi Li; Norio Amizuka; Ken-ichi Miyamoto
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-01

9.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets.

Authors:  N Weidner; D Santa Cruz
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  24 in total

Review 1.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

2.  An 8-year-old with genu valgum: Answers.

Authors:  Kishan Srikanth; Poyyapakkam R Srivaths; Shweta Shah
Journal:  Pediatr Nephrol       Date:  2018-09-26       Impact factor: 3.714

3.  Treatment of ear and bone disease in the Phex mouse mutant with dietary supplementation.

Authors:  Cameron C Wick; Sharon J Lin; Heping Yu; Cliff A Megerian; Qing Yin Zheng
Journal:  Am J Otolaryngol       Date:  2016-09-28       Impact factor: 1.808

4.  FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth.

Authors:  Yue Ma; Beth J Kirby; Nicholas A Fairbridge; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

5.  Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization.

Authors:  Yue Ma; Manoharee Samaraweera; Sandra Cooke-Hubley; Beth J Kirby; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2014-03-06       Impact factor: 4.736

6.  Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport.

Authors:  Qiangmin Zhang; Kunhong Xiao; José M Paredes; Tatyana Mamonova; W Bruce Sneddon; Hongda Liu; Dawei Wang; Sheng Li; Jennifer C McGarvey; David Uehling; Rima Al-Awar; Babu Joseph; Frederic Jean-Alphonse; Angel Orte; Peter A Friedman
Journal:  J Biol Chem       Date:  2019-01-29       Impact factor: 5.157

7.  NHE3 regulatory factor 1 (NHERF1) modulates intestinal sodium-dependent phosphate transporter (NaPi-2b) expression in apical microvilli.

Authors:  Hector Giral; DeeAnn Cranston; Luca Lanzano; Yupanqui Caldas; Eileen Sutherland; Joanna Rachelson; Evgenia Dobrinskikh; Edward J Weinman; R Brian Doctor; Enrico Gratton; Moshe Levi
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

8.  The kidney sodium-phosphate co-transporter alters bone quality in an age and gender specific manner.

Authors:  Adele L Boskey; Lyudmilla Lukashova; Lyudmila Spevak; Yan Ma; Saeed R Khan
Journal:  Bone       Date:  2013-01-17       Impact factor: 4.398

Review 9.  Phosphate and FGF-23 homeostasis after kidney transplantation.

Authors:  Leandro C Baia; Ita Pfeferman Heilberg; Gerjan Navis; Martin H de Borst
Journal:  Nat Rev Nephrol       Date:  2015-09-29       Impact factor: 28.314

10.  1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6.

Authors:  Rimpi K Saini; Ichiro Kaneko; Peter W Jurutka; Ryan Forster; Antony Hsieh; Jui-Cheng Hsieh; Mark R Haussler; G Kerr Whitfield
Journal:  Calcif Tissue Int       Date:  2012-12-22       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.